{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T02:54:51Z","timestamp":1791860091020,"version":"4.3.4"},"reference-count":267,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal.chestnet.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Chest"],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.1378\/chest.11-2293","type":"journal-article","created":{"date-parts":[[2012,2,7]],"date-time":"2012-02-07T02:39:00Z","timestamp":1328582340000},"page":"e89S-e119S","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":354,"special_numbering":"S","title":["Antiplatelet Drugs"],"prefix":"10.1016","volume":"141","author":[{"given":"John W.","family":"Eikelboom","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Hirsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick A.","family":"Spencer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trevor P.","family":"Baglin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey I.","family":"Weitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"24","key":"10.1378\/chest.11-2293_bib1","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMra071014","article-title":"Platelet activation and atherothrombosis","volume":"357","author":"Dav\u00ec","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.11-2293_bib2","series-title":"Thrombosis and Hemorrhage","first-page":"187","article-title":"Mechanisms of platelet activation","author":"Kroll","year":"2002"},{"issue":"suppl 3","key":"10.1378\/chest.11-2293_bib3","doi-asserted-by":"crossref","first-page":"234S","DOI":"10.1378\/chest.126.3_suppl.234S","article-title":"Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy","volume":"126","author":"Patrono","year":"2004","journal-title":"Chest"},{"key":"10.1378\/chest.11-2293_bib4","series-title":"Thrombosis and Hemorrhage","first-page":"122","article-title":"Regulation of megakaryopoiesis","author":"Kaushansky","year":"2002"},{"issue":"1","key":"10.1378\/chest.11-2293_bib5","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1182\/asheducation-2009.1.147","article-title":"Determinants of platelet number and regulation of thrombopoiesis","volume":"2009","author":"Kaushansky","year":"2009","journal-title":"Hematology (Am Soc Hematol Educ Program)"},{"issue":"11","key":"10.1378\/chest.11-2293_bib6","doi-asserted-by":"crossref","first-page":"7634","DOI":"10.1073\/pnas.112202999","article-title":"Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets","volume":"99","author":"Rocca","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"10.1378\/chest.11-2293_bib7","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1083\/jcb.200105058","article-title":"Activated platelets mediate inflammatory signaling by regulated interleukin 1beta synthesis","volume":"154","author":"Lindemann","year":"2001","journal-title":"J Cell Biol"},{"issue":"6 suppl","key":"10.1378\/chest.11-2293_bib8","doi-asserted-by":"crossref","first-page":"199S","DOI":"10.1378\/chest.08-0672","article-title":"Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)","volume":"133","author":"Patrono","year":"2008","journal-title":"Chest"},{"issue":"22","key":"10.1378\/chest.11-2293_bib9","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1056\/NEJMra052717","article-title":"Low-dose aspirin for the prevention of atherothrombosis","volume":"353","author":"Patrono","year":"2005","journal-title":"N Engl J Med"},{"issue":"7329","key":"10.1378\/chest.11-2293_bib10","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","article-title":"Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients","volume":"324","author":"Antithrombotic Trialists' Collaboration","year":"2002","journal-title":"BMJ"},{"issue":"2","key":"10.1378\/chest.11-2293_bib11","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1172\/JCI108941","article-title":"Inhibition of platelet prostaglandin synthetase by oral aspirin","volume":"61","author":"Burch","year":"1978","journal-title":"J Clin Invest"},{"issue":"5","key":"10.1378\/chest.11-2293_bib12","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1172\/JCI111110","article-title":"Arachidonate metabolism in vascular disorders","volume":"72","author":"Majerus","year":"1983","journal-title":"J Clin Invest"},{"issue":"3","key":"10.1378\/chest.11-2293_bib13","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1172\/JCI108132","article-title":"The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate fraction protein","volume":"56","author":"Roth","year":"1975","journal-title":"J Clin Invest"},{"issue":"8","key":"10.1378\/chest.11-2293_bib14","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1073\/pnas.72.8.3073","article-title":"Acetylation of prostaglandin synthase by aspirin","volume":"72","author":"Roth","year":"1975","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"52","key":"10.1378\/chest.11-2293_bib15","doi-asserted-by":"crossref","first-page":"33157","DOI":"10.1074\/jbc.271.52.33157","article-title":"Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2","volume":"271","author":"Smith","year":"1996","journal-title":"J Biol Chem"},{"issue":"8","key":"10.1378\/chest.11-2293_bib16","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/nsb0895-637","article-title":"The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase","volume":"2","author":"Loll","year":"1995","journal-title":"Nat Struct Biol"},{"issue":"1","key":"10.1378\/chest.11-2293_bib17","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1073\/pnas.96.1.272","article-title":"Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2","volume":"96","author":"McAdam","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"16","key":"10.1378\/chest.11-2293_bib18","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1056\/NEJM199110173251605","article-title":"Suppression of thromboxane A2 but not of systemic prostacyclin by controlled-release aspirin","volume":"325","author":"Clarke","year":"1991","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1378\/chest.11-2293_bib19","doi-asserted-by":"crossref","first-page":"10417","DOI":"10.1073\/pnas.93.19.10417","article-title":"Identification of vascular endothelial genes differentially responsive to fluid mechanical stimuli: cyclooxygenase-2, manganese superoxide dismutase, and endothelial cell nitric oxide synthase are selectively up-regulated by steady laminar shear stress","volume":"93","author":"Topper","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"10.1378\/chest.11-2293_bib20","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1172\/JCI110814","article-title":"Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man","volume":"71","author":"FitzGerald","year":"1983","journal-title":"J Clin Invest"},{"issue":"6643","key":"10.1378\/chest.11-2293_bib21","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/41780","article-title":"Altered pain perception and inflammatory response in mice lacking prostacyclin receptor","volume":"388","author":"Murata","year":"1997","journal-title":"Nature"},{"issue":"7553","key":"10.1378\/chest.11-2293_bib22","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1136\/bmj.332.7553.1302","article-title":"Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials","volume":"332","author":"Kearney","year":"2006","journal-title":"BMJ"},{"issue":"1","key":"10.1378\/chest.11-2293_bib23","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1172\/JCI27291","article-title":"Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities","volume":"116","author":"Grosser","year":"2006","journal-title":"J Clin Invest"},{"issue":"19","key":"10.1378\/chest.11-2293_bib24","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJM198411083111902","article-title":"Dose-related kinetics of aspirin. Presystemic acetylation of platelet cyclooxygenase","volume":"311","author":"Pedersen","year":"1984","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1378\/chest.11-2293_bib25","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1161\/01.STR.0000231683.43347.ec","article-title":"Effect of enteric coating on antiplatelet activity of low-dose aspirin in healthy volunteers","volume":"37","author":"Cox","year":"2006","journal-title":"Stroke"},{"issue":"2","key":"10.1378\/chest.11-2293_bib26","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S0022-3565(25)12907-8","article-title":"Transdermal modification of platelet function: an aspirin patch system results in marked suppression of platelet cyclooxygenase","volume":"277","author":"McAdam","year":"1996","journal-title":"J Pharmacol Exp Ther"},{"issue":"9098","key":"10.1378\/chest.11-2293_bib27","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0140-6736(97)11475-1","volume":"351","year":"1998","journal-title":"Lancet"},{"issue":"6","key":"10.1378\/chest.11-2293_bib28","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1161\/01.CIR.72.6.1177","article-title":"Clinical pharmacology of platelet cyclooxygenase inhibition","volume":"72","author":"Patrono","year":"1985","journal-title":"Circulation"},{"issue":"10","key":"10.1378\/chest.11-2293_bib29","doi-asserted-by":"crossref","first-page":"5181","DOI":"10.1073\/pnas.75.10.5181","article-title":"Sensitivity of fatty acid cyclooxygenase from human aorta to acetylation by aspirin","volume":"75","author":"Burch","year":"1978","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"10.1378\/chest.11-2293_bib30","first-page":"196","article-title":"The role of prostaglandins in platelet function","volume":"16","author":"Burch","year":"1979","journal-title":"Semin Hematol"},{"issue":"1","key":"10.1378\/chest.11-2293_bib31","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3181\/00379727-163-40716","article-title":"The effects of aspirin on megakaryocyte prostaglandin production","volume":"163","author":"Demers","year":"1980","journal-title":"Proc Soc Exp Biol Med"},{"issue":"3\u20134","key":"10.1378\/chest.11-2293_bib32","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/0049-3848(80)90334-5","article-title":"Possible significance of small numbers of functional platelets in a population of aspirin-treated platelets in vitro and in vivo","volume":"18","author":"Cerskus","year":"1980","journal-title":"Thromb Res"},{"issue":"7546","key":"10.1378\/chest.11-2293_bib33","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S0140-6736(68)92228-9","article-title":"Effects of salicylates on human platelets","volume":"1","author":"O'Brien","year":"1968","journal-title":"Lancet"},{"issue":"1","key":"10.1378\/chest.11-2293_bib34","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1182\/blood.V69.1.180.180","article-title":"Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs","volume":"69","author":"Reilly","year":"1987","journal-title":"Blood"},{"issue":"6","key":"10.1378\/chest.11-2293_bib35","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1172\/JCI110576","article-title":"Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects","volume":"69","author":"Patrignani","year":"1982","journal-title":"J Clin Invest"},{"issue":"8719","key":"10.1378\/chest.11-2293_bib36","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/0140-6736(90)92336-G","article-title":"Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease","volume":"336","author":"The RISC Group","year":"1990","journal-title":"Lancet"},{"issue":"8833","key":"10.1378\/chest.11-2293_bib37","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/0140-6736(92)92619-Q","article-title":"Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris","volume":"340","author":"Juul-M\u00f6ller","year":"1992","journal-title":"Lancet"},{"issue":"8779","key":"10.1378\/chest.11-2293_bib38","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/0140-6736(91)92233-R","article-title":"Swedish Aspirin Low-Dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events","volume":"338","author":"The SALT Collaborative Group","year":"1991","journal-title":"Lancet"},{"issue":"8","key":"10.1378\/chest.11-2293_bib39","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1161\/01.STR.24.8.1125","article-title":"Does low-dose acetylsalicylic acid prevent stroke after carotid surgery? A double-blind, placebo-controlled randomized trial","volume":"24","author":"Lindblad","year":"1993","journal-title":"Stroke"},{"issue":"1\u20132","key":"10.1378\/chest.11-2293_bib40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0022-510X(96)00308-5","article-title":"European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke","volume":"143","author":"Diener","year":"1996","journal-title":"J Neurol Sci"},{"issue":"2","key":"10.1378\/chest.11-2293_bib41","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1056\/NEJMoa035572","article-title":"Efficacy and safety of low-dose aspirin in polycythemia vera","volume":"350","author":"Landolfi","year":"2004","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1378\/chest.11-2293_bib42","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1136\/jnnp.54.12.1044","article-title":"The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results","volume":"54","author":"Farrell","year":"1991","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"10.1378\/chest.11-2293_bib43","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2106\/00004623-198264010-00010","article-title":"High and low-dose aspirin prophylaxis against venous thromboembolic disease in total hip replacement","volume":"64","author":"Harris","year":"1982","journal-title":"J Bone Joint Surg Am"},{"issue":"1","key":"10.1378\/chest.11-2293_bib44","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2106\/00004623-198567010-00008","article-title":"Prophylaxis of deep-vein thrombosis after total hip replacement. Dextran and external pneumatic compression compared with 1.2 or 0.3 gram of aspirin daily","volume":"67","author":"Harris","year":"1985","journal-title":"J Bone Joint Surg Am"},{"issue":"6213","key":"10.1378\/chest.11-2293_bib45","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1136\/bmj.280.6213.514","article-title":"Prevention of venous thromboembolism after total knee replacement by high-dose aspirin or intermittent calf and thigh compression","volume":"280","author":"McKenna","year":"1980","journal-title":"BMJ"},{"issue":"9171","key":"10.1378\/chest.11-2293_bib46","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1016\/S0140-6736(99)05388-X","article-title":"Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy: a randomised controlled trial. ASA and Carotid Endarterectomy (ACE) Trial Collaborators","volume":"353","author":"Taylor","year":"1999","journal-title":"Lancet"},{"issue":"18","key":"10.1378\/chest.11-2293_bib47","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1056\/NEJM199110313251801","article-title":"A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke","volume":"325","author":"The Dutch TIA Trial Study Group","year":"1991","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1378\/chest.11-2293_bib48","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1056\/NEJMoa0909475","article-title":"Dose comparisons of clopidogrel and aspirin in acute coronary syndromes [published correction appears in N Engl J Med2010;363(16):1585]","volume":"363","author":"Mehta","year":"2010","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1378\/chest.11-2293_bib49","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1056\/NEJM198308183090703","article-title":"Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study","volume":"309","author":"Lewis","year":"1983","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1378\/chest.11-2293_bib50","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1056\/NEJM198810273191701","article-title":"Aspirin, heparin, or both to treat acute unstable angina","volume":"319","author":"Th\u00e9roux","year":"1988","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1378\/chest.11-2293_bib51","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1056\/NEJM198511283132201","article-title":"Aspirin, sulfinpyrazone, or both in unstable angina. Results of a Canadian multicenter trial","volume":"313","author":"Cairns","year":"1985","journal-title":"N Engl J Med"},{"issue":"8389","key":"10.1378\/chest.11-2293_bib52","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S0140-6736(84)92446-2","article-title":"Improved aortocoronary bypass patency by low-dose aspirin (100 mg daily). Effects on platelet aggregation and thromboxane formation","volume":"1","author":"Lorenz","year":"1984","journal-title":"Lancet"},{"issue":"6","key":"10.1378\/chest.11-2293_bib53","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1161\/01.CIR.77.6.1324","article-title":"Improvement in early saphenous vein graft patency after coronary artery bypass surgery with antiplatelet therapy: results of a Veterans Administration Cooperative Study","volume":"77","author":"Goldman","year":"1988","journal-title":"Circulation"},{"issue":"1","key":"10.1378\/chest.11-2293_bib54","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1161\/01.CIR.72.1.138","article-title":"Improved graft patency in patients treated with platelet-inhibiting therapy after coronary bypass surgery","volume":"72","author":"Brown","year":"1985","journal-title":"Circulation"},{"issue":"8","key":"10.1378\/chest.11-2293_bib55","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1056\/NEJM199308193290802","article-title":"A comparison of aspirin with placebo in patients treated with warfarin after heart-valve replacement","volume":"329","author":"Turpie","year":"1993","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1378\/chest.11-2293_bib56","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0022-5223(19)40105-0","article-title":"Aspirin and prophylaxis of thromboembolic complications in patients with substitute heart valves","volume":"72","author":"Altman","year":"1976","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"9","key":"10.1378\/chest.11-2293_bib57","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/0002-9149(83)90673-2","article-title":"Trial of combined warfarin plus dipyridamole or aspirin therapy in prosthetic heart valve replacement: danger of aspirin compared with dipyridamole","volume":"51","author":"Chesebro","year":"1983","journal-title":"Am J Cardiol"},{"issue":"1","key":"10.1378\/chest.11-2293_bib58","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0002-8703(77)80351-7","article-title":"Prevention of arterial thromboembolism with acetylsalicylic acid. A controlled clinical study in patients with aortic ball valves","volume":"94","author":"Dale","year":"1977","journal-title":"Am Heart J"},{"issue":"11","key":"10.1378\/chest.11-2293_bib59","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1056\/NEJM197909133011103","article-title":"Prevention of thrombosis in patients on hemodialysis by low-dose aspirin","volume":"301","author":"Harter","year":"1979","journal-title":"N Engl J Med"},{"issue":"6 suppl A","key":"10.1378\/chest.11-2293_bib60","first-page":"A3","article-title":"ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2","volume":"12","year":"1988","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"10.1378\/chest.11-2293_bib61","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1161\/01.STR.27.4.588","article-title":"Aspirin dose in stroke prevention: beautiful hypotheses slain by ugly facts","volume":"27","author":"Barnett","year":"1996","journal-title":"Stroke"},{"issue":"1","key":"10.1378\/chest.11-2293_bib62","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1161\/01.STR.14.1.5","article-title":"\u201cAICLA\u201d controlled trial of aspirin and dipyridamole in the secondary prevention of athero-thrombotic cerebral ischemia","volume":"14","author":"Bousser","year":"1983","journal-title":"Stroke"},{"issue":"3","key":"10.1378\/chest.11-2293_bib63","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1161\/01.STR.8.3.301","article-title":"Controlled trial of aspirin in cerebral ischemia","volume":"8","author":"Fields","year":"1977","journal-title":"Stroke"},{"issue":"9066","key":"10.1378\/chest.11-2293_bib64","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/S0140-6736(97)04010-5","article-title":"CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke","volume":"349","author":"Chen","year":"1997","journal-title":"Lancet"},{"issue":"9065","key":"10.1378\/chest.11-2293_bib65","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S0140-6736(97)04011-7","article-title":"The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke","volume":"349","author":"International Stroke Trial Collaborative Group","year":"1997","journal-title":"Lancet"},{"issue":"3","key":"10.1378\/chest.11-2293_bib66","first-page":"172","article-title":"Adverse effects of antiaggregating platelet therapy in the treatment of polycythemia vera","volume":"23","author":"Tartaglia","year":"1986","journal-title":"Semin Hematol"},{"issue":"14","key":"10.1378\/chest.11-2293_bib67","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1161\/01.CIR.0000091201.39590.CB","article-title":"Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study","volume":"108","author":"Peters","year":"2003","journal-title":"Circulation"},{"issue":"5","key":"10.1378\/chest.11-2293_bib68","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/0049-3848(82)90127-X","article-title":"Aspirin inhibits platelet function independent of the acetylation of cyclo-oxygenase","volume":"25","author":"Buchanan","year":"1982","journal-title":"Thromb Res"},{"issue":"6","key":"10.1378\/chest.11-2293_bib69","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1172\/JCI113020","article-title":"Aspirin prolongs bleeding time in uremia by a mechanism distinct from platelet cyclooxygenase inhibition","volume":"79","author":"Gaspari","year":"1987","journal-title":"J Clin Invest"},{"issue":"5","key":"10.1378\/chest.11-2293_bib70","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1172\/JCI111865","article-title":"Effects of platelet-modifying drugs on arterial thromboembolism in baboons. Aspirin potentiates the antithrombotic actions of dipyridamole and sulfinpyrazone by mechanism(s) independent of platelet cyclooxygenase inhibition","volume":"75","author":"Hanson","year":"1985","journal-title":"J Clin Invest"},{"issue":"6 Suppl B","key":"10.1378\/chest.11-2293_bib71","doi-asserted-by":"crossref","first-page":"21B","DOI":"10.1016\/S0735-1097(86)80004-3","article-title":"Pharmacology of platelet inhibitors","volume":"8","author":"Harker","year":"1986","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1378\/chest.11-2293_bib72","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1161\/01.CIR.85.3.1077","article-title":"High-dose aspirin inhibits shear-induced platelet reaction involving thrombin generation","volume":"85","author":"Ratnatunga","year":"1992","journal-title":"Circulation"},{"issue":"3","key":"10.1378\/chest.11-2293_bib73","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/S0022-3565(25)24098-8","article-title":"Effects of N-deacetylation and N-desulfation of heparin on its anticoagulant activity and in vivo disposition","volume":"245","author":"Bjornsson","year":"1988","journal-title":"J Pharmacol Exp Ther"},{"issue":"6","key":"10.1378\/chest.11-2293_bib74","first-page":"394","article-title":"Fibrinolytic activity after administration of diflunisal and aspirin. A double-blind, randomized, placebo-controlled clinical trial","volume":"13","author":"Green","year":"1983","journal-title":"Haemostasis"},{"issue":"10","key":"10.1378\/chest.11-2293_bib75","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1056\/NEJM197703102961001","article-title":"Increased blood fibrinolytic activity after aspirin ingestion","volume":"296","author":"Moroz","year":"1977","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1378\/chest.11-2293_bib76","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1055\/s-0038-1648815","article-title":"Measurement of thrombin generation in whole blood\u2014the effect of heparin and aspirin","volume":"72","author":"Kessels","year":"1994","journal-title":"Thromb Haemost"},{"issue":"4","key":"10.1378\/chest.11-2293_bib77","first-page":"239","article-title":"Dose-dependent influence of acetylsalicyclic acid on platelet functions and plasmatic coagulation factors","volume":"5","author":"Loew","year":"1976","journal-title":"Haemostasis"},{"key":"10.1378\/chest.11-2293_bib78","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0022-3565(25)25723-8","article-title":"Influence of acetylsalicylic acid and salicylaide on the coagulation of blood","volume":"128","author":"Quick","year":"1960","journal-title":"J Pharmacol Exp Ther"},{"issue":"8","key":"10.1378\/chest.11-2293_bib79","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1182\/blood.V80.8.2006.2006","article-title":"Antiplatelet drugs and generation of thrombin in clotting blood","volume":"80","author":"Szczeklik","year":"1992","journal-title":"Blood"},{"issue":"25","key":"10.1378\/chest.11-2293_bib80","doi-asserted-by":"crossref","first-page":"3156","DOI":"10.1161\/CIRCULATIONAHA.106.675587","article-title":"Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study","volume":"115","author":"Gurbel","year":"2007","journal-title":"Circulation"},{"issue":"8","key":"10.1378\/chest.11-2293_bib81","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/j.jacc.2005.01.045","article-title":"Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects","volume":"45","author":"Capone","year":"2005","journal-title":"J Am Coll Cardiol"},{"issue":"25","key":"10.1378\/chest.11-2293_bib82","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa003199","article-title":"Cyclooxygenase inhibitors and the antiplatelet effects of aspirin","volume":"345","author":"Catella-Lawson","year":"2001","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1378\/chest.11-2293_bib83","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.clpt.2006.05.004","article-title":"Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease","volume":"80","author":"Renda","year":"2006","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"10.1378\/chest.11-2293_bib84","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1056\/NEJM200108093450607","article-title":"The coxibs, selective inhibitors of cyclooxygenase-2","volume":"345","author":"FitzGerald","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.11-2293_bib85","series-title":"Information for Healthcare Professionals: Concomitant Use of Ibuprofen and Aspirin","author":"US Food and Drug Administration","year":"2010"},{"issue":"2","key":"10.1378\/chest.11-2293_bib86","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1056\/NEJM197807132990201","article-title":"A randomized trial of aspirin and sulfinpyrazone in threatened stroke","volume":"299","author":"The Canadian Cooperative Study Group","year":"1978","journal-title":"N Engl J Med"},{"issue":"9678","key":"10.1378\/chest.11-2293_bib87","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(09)60503-1","article-title":"Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials","volume":"373","author":"Baigent","year":"2009","journal-title":"Lancet"},{"issue":"9250","key":"10.1378\/chest.11-2293_bib88","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0140-6736(00)03539-X","article-title":"Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice","volume":"357","author":"de Gaetano","year":"2001","journal-title":"Lancet"},{"issue":"9118","key":"10.1378\/chest.11-2293_bib89","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/S0140-6736(98)04311-6","article-title":"Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial","volume":"351","author":"Hansson","year":"1998","journal-title":"Lancet"},{"issue":"6618","key":"10.1378\/chest.11-2293_bib90","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1136\/bmj.296.6618.313","article-title":"Randomised trial of prophylactic daily aspirin in British male doctors","volume":"296","author":"Peto","year":"1988","journal-title":"Br Med J (Clin Res Ed)"},{"issue":"13","key":"10.1378\/chest.11-2293_bib91","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1056\/NEJMoa050613","article-title":"A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women","volume":"352","author":"Ridker","year":"2005","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1378\/chest.11-2293_bib92","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJM198907203210301","article-title":"Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study","volume":"321","year":"1989","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1378\/chest.11-2293_bib93","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1001\/jama.2008.623","article-title":"Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial","volume":"300","author":"Ogawa","year":"2008","journal-title":"JAMA"},{"key":"10.1378\/chest.11-2293_bib94","doi-asserted-by":"crossref","first-page":"a1840","DOI":"10.1136\/bmj.a1840","article-title":"The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease","volume":"337","author":"Belch","year":"2008","journal-title":"BMJ"},{"issue":"9","key":"10.1378\/chest.11-2293_bib95","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1001\/jama.2010.221","article-title":"Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial","volume":"303","author":"Fowkes","year":"2010","journal-title":"JAMA"},{"issue":"7","key":"10.1378\/chest.11-2293_bib96","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.amjmed.2011.01.018","article-title":"Effect of aspirin on mortality in primary prevention of cardiovascular disease","volume":"124","author":"Raju","year":"2011","journal-title":"Am J Med"},{"key":"10.1378\/chest.11-2293_bib97","series-title":"Japanese Primary Prevention Project with Aspirin","author":"Ikeda","year":"2005"},{"issue":"12","key":"10.1378\/chest.11-2293_bib98","doi-asserted-by":"crossref","first-page":"897","DOI":"10.2165\/00002512-200320120-00004","article-title":"Rationale for a trial of low-dose aspirin for the primary prevention of major adverse cardiovascular events and vascular dementia in the elderly: Aspirin in Reducing Events in the Elderly (ASPREE)","volume":"20","author":"Nelson","year":"2003","journal-title":"Drugs Aging"},{"key":"10.1378\/chest.11-2293_bib99","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1745-6215-8-21","volume":"8","author":"De Berardis","year":"2007","journal-title":"Trials"},{"issue":"2 suppl","key":"10.1378\/chest.11-2293_bib100","doi-asserted-by":"crossref","first-page":"e637S","DOI":"10.1378\/chest.11-2306","article-title":"Primary and secondary prevention of cardiovascular disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines","volume":"141","author":"Vandvik","year":"2012","journal-title":"Chest"},{"issue":"12","key":"10.1378\/chest.11-2293_bib101","doi-asserted-by":"crossref","first-page":"857","DOI":"10.7326\/0003-4819-146-12-200706190-00007","article-title":"Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation","volume":"146","author":"Hart","year":"2007","journal-title":"Ann Intern Med"},{"issue":"19","key":"10.1378\/chest.11-2293_bib102","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1056\/NEJMc1007378","article-title":"Newly identified events in the RE-LY trial","volume":"363","author":"Connolly","year":"2010","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1378\/chest.11-2293_bib103","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1056\/NEJMoa1007432","article-title":"Apixaban in patients with atrial fibrillation","volume":"364","author":"Connolly","year":"2011","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1378\/chest.11-2293_bib104","doi-asserted-by":"crossref","first-page":"590","DOI":"10.7326\/0003-4819-147-8-200710160-00018","article-title":"Adjusted-dose warfarin versus aspirin for preventing stroke in patients with atrial fibrillation","volume":"147","author":"Hart","year":"2007","journal-title":"Ann Intern Med"},{"issue":"9526","key":"10.1378\/chest.11-2293_bib105","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/S0140-6736(06)68845-4","article-title":"Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial","volume":"367","author":"Connolly","year":"2006","journal-title":"Lancet"},{"issue":"20","key":"10.1378\/chest.11-2293_bib106","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1056\/NEJMoa0901301","article-title":"Effect of clopidogrel added to aspirin in patients with atrial fibrillation","volume":"360","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"issue":"2 suppl","key":"10.1378\/chest.11-2293_bib107","doi-asserted-by":"crossref","first-page":"e531S","DOI":"10.1378\/chest.11-2304","article-title":"Antithrombotic therapy for atrial fibrillation: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines","volume":"141","author":"You","year":"2012","journal-title":"Chest"},{"issue":"9212","key":"10.1378\/chest.11-2293_bib108","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/S0140-6736(00)02110-3","article-title":"Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial","volume":"355","author":"Pulmonary Embolism Prevention (PEP) trial Collaborative Group","year":"2000","journal-title":"Lancet"},{"issue":"6921","key":"10.1378\/chest.11-2293_bib109","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1136\/bmj.308.6921.81","article-title":"Collaborative overview of randomised trials of antiplatelet therapy\u2014I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients","volume":"308","author":"Antiplatelet Trialists' Collaboration","year":"1994","journal-title":"BMJ"},{"issue":"4","key":"10.1378\/chest.11-2293_bib110","first-page":"CD000024","article-title":"Anticoagulants for acute ischaemic stroke","author":"Sandercock","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"10.1378\/chest.11-2293_bib111","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/j.1365-2141.2009.07734.x","article-title":"Does acetyl salicylic acid (ASA) have a role in the prevention of venous thromboembolism?","volume":"146","author":"Karthikeyan","year":"2009","journal-title":"Br J Haematol"},{"issue":"2 suppl","key":"10.1378\/chest.11-2293_bib112","doi-asserted-by":"crossref","first-page":"e278S","DOI":"10.1378\/chest.11-2404","article-title":"Prevention of VTE in orthopedic surgery patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines","volume":"141","author":"Falck-Ytter","year":"2012","journal-title":"Chest"},{"issue":"2","key":"10.1378\/chest.11-2293_bib113","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1001\/jama.1991.03470020086038","article-title":"A meta-analysis of low-dose aspirin for the prevention of pregnancy-induced hypertensive disease","volume":"266","author":"Imperiale","year":"1991","journal-title":"JAMA"},{"issue":"8755","key":"10.1378\/chest.11-2293_bib114","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/0140-6736(91)93124-R","article-title":"Prevention of fetal growth retardation with low-dose aspirin: findings of the EPREDA trial","volume":"337","author":"Uzan","year":"1991","journal-title":"Lancet"},{"issue":"11","key":"10.1378\/chest.11-2293_bib115","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1056\/NEJM199803123381101","article-title":"Low-dose aspirin to prevent preeclampsia in women at high risk","volume":"338","author":"Caritis","year":"1998","journal-title":"N Engl J Med"},{"issue":"8898","key":"10.1378\/chest.11-2293_bib116","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S0140-6736(94)92633-6","article-title":"CLASP: a randomised trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women","volume":"343","author":"CLASP (Collaborative Low-dose Aspirin Study in Pregnancy) Collaborative Group","year":"1994","journal-title":"Lancet"},{"issue":"1","key":"10.1378\/chest.11-2293_bib117","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1471-0528.1996.tb09513.x","article-title":"ECPPA: randomised trial of low dose aspirin for the prevention of maternal and fetal complications in high risk pregnant women. ECPPA (Estudo Colaborativo para Preven\u00e7\u00e3o da Pr\u00e9-eclampsia com Aspirina) Collaborative Group","volume":"103","author":"ECPPA","year":"1996","journal-title":"Br J Obstet Gynaecol"},{"issue":"3","key":"10.1378\/chest.11-2293_bib118","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/j.1471-0528.1998.tb10089.x","article-title":"A randomised trial of low dose aspirin for primiparae in pregnancy","volume":"105","author":"Golding","year":"1998","journal-title":"Br J Obstet Gynaecol"},{"issue":"8842","key":"10.1378\/chest.11-2293_bib119","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/0140-6736(93)92988-6","article-title":"Low-dose aspirin in prevention and treatment of intrauterine growth retardation and pregnancy-induced hypertension. Italian study of aspirin in pregnancy","volume":"341","year":"1993","journal-title":"Lancet"},{"issue":"3","key":"10.1378\/chest.11-2293_bib120","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/j.1471-0528.1998.tb10088.x","article-title":"Barbados Low Dose Aspirin Study in Pregnancy (BLASP): a randomised trial for the prevention of pre-eclampsia and its complications","volume":"105","author":"Rotchell","year":"1998","journal-title":"Br J Obstet Gynaecol"},{"issue":"17","key":"10.1378\/chest.11-2293_bib121","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1056\/NEJM199310213291701","article-title":"Prevention of preeclampsia with low-dose aspirin in healthy, nulliparous pregnant women","volume":"329","author":"Sibai","year":"1993","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1378\/chest.11-2293_bib122","first-page":"CD004659","article-title":"Antiplatelet agents for preventing pre-eclampsia and its complications","author":"Duley","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"issue":"9575","key":"10.1378\/chest.11-2293_bib123","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1016\/S0140-6736(07)60712-0","article-title":"Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data","volume":"369","author":"Askie","year":"2007","journal-title":"Lancet"},{"issue":"2 suppl","key":"10.1378\/chest.11-2293_bib124","first-page":"e691S","article-title":"VTE, thrombophilia, antithrombotic therapy, and pregnancy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines","volume":"141","author":"SM","year":"2012","journal-title":"Chest"},{"issue":"9759","key":"10.1378\/chest.11-2293_bib125","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(10)62110-1","article-title":"Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials","volume":"377","author":"Rothwell","year":"2011","journal-title":"Lancet"},{"issue":"9754","key":"10.1378\/chest.11-2293_bib126","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/S0140-6736(10)61543-7","article-title":"Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials","volume":"376","author":"Rothwell","year":"2010","journal-title":"Lancet"},{"issue":"3","key":"10.1378\/chest.11-2293_bib127","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1365-2125.1993.tb05689.x","article-title":"The gastrointestinal toxicity of aspirin: an overview of randomised controlled trials","volume":"35","author":"Roderick","year":"1993","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"10.1378\/chest.11-2293_bib128","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1001\/archinte.158.1.33","article-title":"Risk of hospitalization for upper gastrointestinal tract bleeding associated with ketorolac, other nonsteroidal anti-inflammatory drugs, calcium antagonists, and other antihypertensive drugs","volume":"158","author":"Garc\u00eda Rodr\u00edguez","year":"1998","journal-title":"Arch Intern Med"},{"issue":"6983","key":"10.1378\/chest.11-2293_bib129","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1136\/bmj.310.6983.827","article-title":"Prophylactic aspirin and risk of peptic ulcer bleeding","volume":"310","author":"Weil","year":"1995","journal-title":"BMJ"},{"issue":"5","key":"10.1378\/chest.11-2293_bib130","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1046\/j.0306-5251.2001.01476.x","article-title":"Association between aspirin and upper gastrointestinal complications: systematic review of epidemiologic studies","volume":"52","author":"Garc\u00eda Rodr\u00edguez","year":"2001","journal-title":"Br J Clin Pharmacol"},{"issue":"8","key":"10.1378\/chest.11-2293_bib131","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1111\/j.1572-0241.2005.41833.x","article-title":"A nationwide study of mortality associated with hospital admission due to severe gastrointestinal events and those associated with nonsteroidal antiinflammatory drug use","volume":"100","author":"Lanas","year":"2005","journal-title":"Am J Gastroenterol"},{"issue":"24","key":"10.1378\/chest.11-2293_bib132","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1056\/NEJM199906173402407","article-title":"Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs","volume":"340","author":"Wolfe","year":"1999","journal-title":"N Engl J Med"},{"issue":"9039","key":"10.1378\/chest.11-2293_bib133","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/S0140-6736(96)01254-8","article-title":"Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product","volume":"348","author":"Kelly","year":"1996","journal-title":"Lancet"},{"key":"10.1378\/chest.11-2293_bib134","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1472-6904-1-1","article-title":"Risk of upper gastrointestinal bleeding and perforation associated with low-dose aspirin as plain and enteric-coated formulations","volume":"1","author":"de Abajo","year":"2001","journal-title":"BMC Clin Pharmacol"},{"issue":"11","key":"10.1378\/chest.11-2293_bib135","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1056\/NEJM199803123381104","article-title":"A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group","volume":"338","author":"Yeomans","year":"1998","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1378\/chest.11-2293_bib136","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJM199803123381105","article-title":"Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group","volume":"338","author":"Hawkey","year":"1998","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1378\/chest.11-2293_bib137","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1056\/NEJM200103293441304","article-title":"Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen","volume":"344","author":"Chan","year":"2001","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1378\/chest.11-2293_bib138","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJMoa042087","article-title":"Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding","volume":"352","author":"Chan","year":"2005","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1378\/chest.11-2293_bib139","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.cgh.2006.04.019","article-title":"Esomeprazole with aspirin versus clopidogrel for prevention of recurrent gastrointestinal ulcer complications","volume":"4","author":"Lai","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"18","key":"10.1378\/chest.11-2293_bib140","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1161\/CIRCULATIONAHA.108.191087","article-title":"ACCF\/ACG\/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents","volume":"118","author":"Bhatt","year":"2008","journal-title":"Circulation"},{"issue":"9","key":"10.1378\/chest.11-2293_bib141","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1161\/01.STR.30.9.1764","article-title":"Prospective study of aspirin use and risk of stroke in women","volume":"30","author":"Iso","year":"1999","journal-title":"Stroke"},{"issue":"3","key":"10.1378\/chest.11-2293_bib142","first-page":"244","article-title":"The effects of nonsteroidal anti-inflammatory drugs on human hypertensive vascular disease","volume":"15","author":"Men\u00e9","year":"1995","journal-title":"Semin Nephrol"},{"issue":"7","key":"10.1378\/chest.11-2293_bib143","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1056\/NEJM198902163200703","article-title":"Improvement of renal function with selective thromboxane antagonism in lupus nephritis","volume":"320","author":"Pierucci","year":"1989","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1378\/chest.11-2293_bib144","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S0735-1097(97)00502-0","article-title":"Antiplatelet agents and survival: a cohort analysis from the Studies of Left Ventricular Dysfunction (SOLVD) trial","volume":"31","author":"Al-Khadra","year":"1998","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"10.1378\/chest.11-2293_bib145","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1016\/S0735-1097(00)00638-0","article-title":"Clinical effects of early angiotensin-converting enzyme inhibitor treatment for acute myocardial infarction are similar in the presence and absence of aspirin: systematic overview of individual data from 96,712 randomized patients","volume":"35","author":"Latini","year":"2000","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"10.1378\/chest.11-2293_bib146","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1097\/00004872-200205000-00038","article-title":"Low-dose aspirin does not interfere with the blood pressure-lowering effects of antihypertensive therapy","volume":"20","author":"Zanchetti","year":"2002","journal-title":"J Hypertens"},{"issue":"9339","key":"10.1378\/chest.11-2293_bib147","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/S0140-6736(02)11138-X","article-title":"Effects of long-term treatment with angiotensin-converting-enzyme inhibitors in the presence or absence of aspirin: a systematic review","volume":"360","author":"Teo","year":"2002","journal-title":"Lancet"},{"issue":"suppl 1","key":"10.1378\/chest.11-2293_bib148","first-page":"S241","article-title":"Antiplatelet drugs","volume":"147","author":"Born","year":"2006","journal-title":"Br J Pharmacol"},{"issue":"5","key":"10.1378\/chest.11-2293_bib149","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1161\/01.CIR.0000154607.90506.45","article-title":"Dipyridamole selectively inhibits inflammatory gene expression in platelet-monocyte aggregates","volume":"111","author":"Weyrich","year":"2005","journal-title":"Circulation"},{"issue":"2","key":"10.1378\/chest.11-2293_bib150","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/j.1365-2125.1990.tb03763.x","article-title":"Dipyridamole alone or combined with low-dose acetylsalicylic acid inhibits platelet aggregation in human whole blood ex vivo","volume":"30","author":"M\u00fcller","year":"1990","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"10.1378\/chest.11-2293_bib151","first-page":"CD001820","article-title":"Dipyridamole for preventing stroke and other vascular events in patients with vascular disease","author":"De Schryver","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"issue":"9523","key":"10.1378\/chest.11-2293_bib152","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S0140-6736(06)68734-5","article-title":"Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial","volume":"367","author":"Halkes","year":"2006","journal-title":"Lancet"},{"issue":"12","key":"10.1378\/chest.11-2293_bib153","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1056\/NEJMoa0805002","article-title":"Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke","volume":"359","author":"Sacco","year":"2008","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1378\/chest.11-2293_bib154","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1161\/STROKEAHA.107.496281","article-title":"Aspirin plus dipyridamole versus aspirin for prevention of vascular events after stroke or TIA: a meta-analysis","volume":"39","author":"Verro","year":"2008","journal-title":"Stroke"},{"key":"10.1378\/chest.11-2293_bib155","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1161\/STROKEAHA.107.499723","article-title":"Dipyridamole for preventing stroke and other vascular events in patients with vascular disease. an Update","volume":"39","author":"De Schryver","year":"2008","journal-title":"Stroke"},{"issue":"12","key":"10.1378\/chest.11-2293_bib156","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1016\/S0002-9149(02)02869-2","article-title":"Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication","volume":"90","author":"Thompson","year":"2002","journal-title":"Am J Cardiol"},{"issue":"6","key":"10.1378\/chest.11-2293_bib157","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.jstrokecerebrovasdis.2009.07.010","article-title":"Stroke prevention by cilostazol in patients with atherothrombosis: meta-analysis of placebo-controlled randomized trials","volume":"18","author":"Uchiyama","year":"2009","journal-title":"J Stroke Cerebrovasc Dis"},{"issue":"6","key":"10.1378\/chest.11-2293_bib158","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.ahj.2007.12.024","article-title":"Systematic review and meta-analysis of randomized clinical trials appraising the impact of cilostazol after percutaneous coronary intervention","volume":"155","author":"Biondi-Zoccai","year":"2008","journal-title":"Am Heart J"},{"issue":"10","key":"10.1378\/chest.11-2293_bib159","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/S1474-4422(10)70198-8","article-title":"Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial","volume":"9","author":"Shinohara","year":"2010","journal-title":"Lancet Neurol"},{"issue":"2","key":"10.1378\/chest.11-2293_bib160","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1055\/s-2005-869523","article-title":"Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis","volume":"31","author":"Savi","year":"2005","journal-title":"Semin Thromb Hemost"},{"issue":"3","key":"10.1378\/chest.11-2293_bib161","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/j.1538-7836.2009.03714.x","article-title":"Reduction of platelet thromboxane A2 production ex vivo and in vivo by clopidogrel therapy","volume":"8","author":"Armstrong","year":"2010","journal-title":"J Thromb Haemost"},{"issue":"3","key":"10.1378\/chest.11-2293_bib162","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1111\/j.1538-7836.2010.04160.x","article-title":"In the presence of strong P2Y12 receptor blockade, aspirin provides little additional inhibition of platelet aggregation","volume":"9","author":"Armstrong","year":"2010","journal-title":"J Thromb Haemost"},{"issue":"8649","key":"10.1378\/chest.11-2293_bib163","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/S0140-6736(89)92327-1","article-title":"The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke","volume":"1","author":"Gent","year":"1989","journal-title":"Lancet"},{"issue":"8","key":"10.1378\/chest.11-2293_bib164","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1056\/NEJM198908243210804","article-title":"A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients","volume":"321","author":"Hass","year":"1989","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1378\/chest.11-2293_bib165","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1161\/01.CIR.82.1.17","article-title":"Antiplatelet treatment with ticlopidine in unstable angina. A controlled multicenter clinical trial. The Studio della Ticlopidina nell'Angina Instabile Group","volume":"82","author":"Balsano","year":"1990","journal-title":"Circulation"},{"issue":"5","key":"10.1378\/chest.11-2293_bib166","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/S0735-1097(01)01164-0","article-title":"Ticlopidine versus aspirin after myocardial infarction (STAMI) trial","volume":"37","author":"Scrutinio","year":"2001","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"10.1378\/chest.11-2293_bib167","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1177\/000331978803900904","article-title":"Multicenter double-blind study of ticlopidine in the treatment of intermittent claudication and the prevention of its complications","volume":"39","author":"Arcan","year":"1988","journal-title":"Angiology"},{"issue":"1","key":"10.1378\/chest.11-2293_bib168","first-page":"84","article-title":"Ticlopidine in the treatment of intermittent claudication: a 21-month double-blind trial","volume":"114","author":"Balsano","year":"1989","journal-title":"J Lab Clin Med"},{"issue":"5","key":"10.1378\/chest.11-2293_bib169","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.1365-2796.1990.tb00164.x","article-title":"Prevention of myocardial infarction and stroke in patients with intermittent claudication; effects of ticlopidine. Results from STIMS, the Swedish Ticlopidine Multicentre Study","volume":"227","author":"Janzon","year":"1990","journal-title":"J Intern Med"},{"issue":"5","key":"10.1378\/chest.11-2293_bib170","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/S0022-5223(19)36194-X","article-title":"Prevention of aorta-coronary bypass graft occlusion. Beneficial effect of ticlopidine on early and late patency rates of venous coronary bypass grafts: a double-blind study","volume":"94","author":"Limet","year":"1987","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"1","key":"10.1378\/chest.11-2293_bib171","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1161\/01.CIR.82.1.296","article-title":"Ticlopidine in unstable angina. A more expensive aspirin?","volume":"82","author":"FitzGerald","year":"1990","journal-title":"Circulation"},{"issue":"2","key":"10.1378\/chest.11-2293_bib172","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s002770050369","article-title":"Ticlopidine-associated aplastic anemia. A case report and review of literature","volume":"76","author":"Yeh","year":"1998","journal-title":"Ann Hematol"},{"issue":"21","key":"10.1378\/chest.11-2293_bib173","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1001\/archinte.159.21.2524","article-title":"Thrombotic thrombocytopenic purpura associated with ticlopidine in the setting of coronary artery stents and stroke prevention","volume":"159","author":"Bennett","year":"1999","journal-title":"Arch Intern Med"},{"issue":"23","key":"10.1378\/chest.11-2293_bib174","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1056\/NEJM199812033392303","article-title":"A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting","volume":"339","author":"Leon","year":"1998","journal-title":"N Engl J Med"},{"issue":"9046","key":"10.1378\/chest.11-2293_bib175","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/S0140-6736(97)22003-9","article-title":"Antiplatelet rather than anticoagulant therapy with coronary stenting","volume":"349","author":"More","year":"1997","journal-title":"Lancet"},{"issue":"1","key":"10.1378\/chest.11-2293_bib176","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0735-1097(01)01713-2","article-title":"Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting","volume":"39","author":"Bhatt","year":"2002","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"10.1378\/chest.11-2293_bib177","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1001\/jama.281.9.806","article-title":"Incidence and clinical course of thrombotic thrombocytopenic purpura due to ticlopidine following coronary stenting. EPISTENT Investigators. Evaluation of Platelet IIb\/IIIa Inhibitor for Stenting","volume":"281","author":"Steinhubl","year":"1999","journal-title":"JAMA"},{"issue":"5","key":"10.1378\/chest.11-2293_bib178","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1055\/s-0037-1614133","article-title":"Identification and biological activity of the active metabolite of clopidogrel","volume":"84","author":"Savi","year":"2000","journal-title":"Thromb Haemost"},{"issue":"11","key":"10.1378\/chest.11-2293_bib179","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1124\/dmd.30.11.1288","article-title":"Structure and stereochemistry of the active metabolite of clopidogrel","volume":"30","author":"Pereillo","year":"2002","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"10.1378\/chest.11-2293_bib180","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/j.1527-3466.1993.tb00275.x","article-title":"Clopidogrel, a novel antiplatelet and antithrombotic agent","volume":"11","author":"Herbert","year":"1993","journal-title":"Cardiovasc Drug Rev"},{"issue":"suppl 2","key":"10.1378\/chest.11-2293_bib181","first-page":"15","article-title":"Clopidogrel loading dose regimens: kinetic profile of pharmacodynamic response in healthy subjects","volume":"25","author":"Savcic","year":"1999","journal-title":"Semin Thromb Hemost"},{"issue":"20","key":"10.1378\/chest.11-2293_bib182","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1161\/01.CIR.0000160869.75810.98","article-title":"Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention","volume":"111","author":"Hochholzer","year":"2005","journal-title":"Circulation"},{"issue":"19","key":"10.1378\/chest.11-2293_bib183","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1161\/CIRCULATIONAHA.105.559088","volume":"112","author":"von Beckerath","year":"2005","journal-title":"Circulation"},{"issue":"7","key":"10.1378\/chest.11-2293_bib184","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/j.jacc.2006.06.049","article-title":"Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting","volume":"48","author":"Cuisset","year":"2006","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"10.1378\/chest.11-2293_bib185","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.jacc.2006.04.090","volume":"48","author":"Montalescot","year":"2006","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"10.1378\/chest.11-2293_bib186","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.jacc.2010.04.047","article-title":"Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate","volume":"56","author":"Bonello","year":"2010","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1378\/chest.11-2293_bib187","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/j.1476-5381.2010.00881.x","article-title":"Effects of drug interactions on biotransformation and antiplatelet effect of clopidogrel in vitro","volume":"161","author":"Zahno","year":"2010","journal-title":"Br J Pharmacol"},{"issue":"1","key":"10.1378\/chest.11-2293_bib188","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/clpt.2010.219","article-title":"Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies","volume":"89","author":"Angiolillo","year":"2011","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"10.1378\/chest.11-2293_bib189","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0002-9149(03)00626-X","article-title":"Comparison of clinical benefits of clopidogrel therapy in patients with acute coronary syndromes taking atorvastatin versus other statin therapies","volume":"92","author":"Wienbergen","year":"2003","journal-title":"Am J Cardiol"},{"issue":"12","key":"10.1378\/chest.11-2293_bib190","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1111\/j.1538-7836.2010.04049.x","article-title":"Effect of proton pump inhibitors on clinical outcome in patients treated with clopidogrel: a systematic review and meta-analysis","volume":"8","author":"Siller-Matula","year":"2010","journal-title":"J Thromb Haemost"},{"issue":"20","key":"10.1378\/chest.11-2293_bib191","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1007964","article-title":"Clopidogrel with or without omeprazole in coronary artery disease","volume":"363","author":"Bhatt","year":"2010","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1378\/chest.11-2293_bib192","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1136\/hrt.2004.035014","article-title":"Lack of clopidogrel-CYP3A4 statin interaction in patients with acute coronary syndrome","volume":"91","author":"Mukherjee","year":"2005","journal-title":"Heart"},{"issue":"8","key":"10.1378\/chest.11-2293_bib193","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1161\/01.CIR.0000088780.57432.43","article-title":"Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial","volume":"108","author":"Saw","year":"2003","journal-title":"Circulation"},{"issue":"11","key":"10.1378\/chest.11-2293_bib194","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1093\/eurheartj\/ehi139","article-title":"Impact of combined pharmacologic treatment with clopidogrel and a statin on outcomes of patients with non-ST-segment elevation acute coronary syndromes: perspectives from a large multinational registry","volume":"26","author":"Lim","year":"2005","journal-title":"Eur Heart J"},{"issue":"16","key":"10.1378\/chest.11-2293_bib195","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1001\/jama.2010.1543","article-title":"Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis","volume":"304","author":"Mega","year":"2010","journal-title":"JAMA"},{"issue":"9749","key":"10.1378\/chest.11-2293_bib196","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/S0140-6736(10)61274-3","article-title":"Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial","volume":"376","author":"Wallentin","year":"2010","journal-title":"Lancet"},{"issue":"18","key":"10.1378\/chest.11-2293_bib197","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1056\/NEJMoa1008410","article-title":"Effects of CYP2C19 genotype on outcomes of clopidogrel treatment","volume":"363","author":"Par\u00e9","year":"2010","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1378\/chest.11-2293_bib198","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1001\/jama.2010.1566","article-title":"Clopidogrel and the reduced-function CYP2C19 genetic variant: a limited piece of the overall therapeutic puzzle","volume":"304","author":"Fuster","year":"2010","journal-title":"JAMA"},{"issue":"11","key":"10.1378\/chest.11-2293_bib199","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1001\/jama.2011.290","article-title":"Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial [published correction appears in JAMA. 2011;305(21);2174]","volume":"305","author":"Price","year":"2011","journal-title":"JAMA"},{"issue":"3","key":"10.1378\/chest.11-2293_bib200","doi-asserted-by":"crossref","first-page":"289","DOI":"10.2217\/fca.10.20","article-title":"Point-of-care testing for assessment of adequacy of oral antiplatelet therapy in patients with cardiovascular disease","volume":"6","author":"Sobieraj-Teague","year":"2010","journal-title":"Future Cardiol"},{"issue":"9038","key":"10.1378\/chest.11-2293_bib201","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","article-title":"A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)","volume":"348","author":"CAPRIE Steering Committee","year":"1996","journal-title":"Lancet"},{"issue":"24","key":"10.1378\/chest.11-2293_bib202","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1056\/NEJM200006153422402","article-title":"Thrombotic thrombocytopenic purpura associated with clopidogrel","volume":"342","author":"Bennett","year":"2000","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1378\/chest.11-2293_bib203","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1056\/NEJMoa060989","article-title":"Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events","volume":"354","author":"Bhatt","year":"2006","journal-title":"N Engl J Med"},{"issue":"9497","key":"10.1378\/chest.11-2293_bib204","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1016\/S0140-6736(05)67660-X","article-title":"Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial","volume":"366","author":"Chen","year":"2005","journal-title":"Lancet"},{"issue":"9431","key":"10.1378\/chest.11-2293_bib205","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0140-6736(04)16721-4","article-title":"Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial","volume":"364","author":"Diener","year":"2004","journal-title":"Lancet"},{"issue":"12","key":"10.1378\/chest.11-2293_bib206","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1056\/NEJMoa050522","article-title":"Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation","volume":"352","author":"Sabatine","year":"2005","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1378\/chest.11-2293_bib207","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1001\/jama.288.19.2411","article-title":"Clopidogrel for the Reduction of Events During Observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial","volume":"288","author":"Steinhubl","year":"2002","journal-title":"JAMA"},{"issue":"7","key":"10.1378\/chest.11-2293_bib208","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation","volume":"345","author":"Yusuf","year":"2001","journal-title":"N Engl J Med"},{"issue":"9748","key":"10.1378\/chest.11-2293_bib209","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/S0140-6736(10)61088-4","article-title":"Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial","volume":"376","author":"Mehta","year":"2010","journal-title":"Lancet"},{"issue":"7","key":"10.1378\/chest.11-2293_bib210","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1124\/dmd.106.014522","article-title":"The disposition of prasugrel, a novel thienopyridine, in humans","volume":"35","author":"Farid","year":"2007","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"10.1378\/chest.11-2293_bib211","doi-asserted-by":"crossref","first-page":"66.e9","DOI":"10.1016\/j.ahj.2006.10.010","article-title":"A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation","volume":"153","author":"Brandt","year":"2007","journal-title":"Am Heart J"},{"issue":"10","key":"10.1378\/chest.11-2293_bib212","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1093\/eurheartj\/ehi877","article-title":"Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease","volume":"27","author":"Jernberg","year":"2006","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1378\/chest.11-2293_bib213","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1177\/0091270007309709","article-title":"Prasugrel, a new thienopyridine antiplatelet drug, weakly inhibits cytochrome P450 2B6 in humans","volume":"48","author":"Farid","year":"2008","journal-title":"J Clin Pharmacol"},{"issue":"20","key":"10.1378\/chest.11-2293_bib214","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1378\/chest.11-2293_bib215","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ahj.2010.04.022","volume":"160","author":"Chin","year":"2010","journal-title":"Am Heart J"},{"issue":"1","key":"10.1378\/chest.11-2293_bib216","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1172\/JCI110973","article-title":"A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoproteins IIb and\/or IIIa","volume":"72","author":"Coller","year":"1983","journal-title":"J Clin Invest"},{"issue":"suppl 11","key":"10.1378\/chest.11-2293_bib217","first-page":"S57","article-title":"Platelet GPIIb\/IIIa antagonists: the first anti-integrin receptor therapeutics","volume":"100","author":"Coller","year":"1997","journal-title":"J Clin Invest"},{"issue":"4","key":"10.1378\/chest.11-2293_bib218","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1161\/01.CIR.90.4.1757","article-title":"Pharmacodynamics of chimeric glycoprotein IIb\/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty","volume":"90","author":"Tcheng","year":"1994","journal-title":"Circulation"},{"issue":"17","key":"10.1378\/chest.11-2293_bib219","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1161\/01.CIR.97.17.1680","article-title":"Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb\/IIIa receptor blockade","volume":"97","author":"Mascelli","year":"1998","journal-title":"Circulation"},{"issue":"14","key":"10.1378\/chest.11-2293_bib220","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1056\/NEJM199404073301402","article-title":"Use of a monoclonal antibody directed against the platelet glycoprotein IIb\/IIIa receptor in high-risk coronary angioplasty","volume":"330","author":"The EPIC Investigators","year":"1994","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1378\/chest.11-2293_bib221","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1161\/hc3301.094533","article-title":"Abciximab readministration: results of the ReoPro Readministration Registry","volume":"104","author":"Tcheng","year":"2001","journal-title":"Circulation"},{"issue":"4","key":"10.1378\/chest.11-2293_bib222","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S0002-9149(99)00768-7","article-title":"Efficacy of abciximab readministration in coronary intervention","volume":"85","author":"Madan","year":"2000","journal-title":"Am J Cardiol"},{"issue":"6","key":"10.1378\/chest.11-2293_bib223","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1182\/blood.V99.6.2054","article-title":"Thrombocytopenia after second exposure to abciximab is caused by antibodies that recognize abciximab-coated platelets","volume":"99","author":"Curtis","year":"2002","journal-title":"Blood"},{"issue":"24","key":"10.1378\/chest.11-2293_bib224","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1056\/NEJM199706123362401","article-title":"Platelet glycoprotein IIb\/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization","volume":"336","author":"The EPILOG Investigators","year":"1997","journal-title":"N Engl J Med"},{"issue":"4 pt 2","key":"10.1378\/chest.11-2293_bib225","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1053\/hj.1999.v138.a100465","article-title":"Understanding thrombocytopenia and antigenicity with glycoprotein IIb-IIIa inhibitors","volume":"138","author":"Madan","year":"1999","journal-title":"Am Heart J"},{"issue":"16","key":"10.1378\/chest.11-2293_bib226","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1021\/jm00042a007","article-title":"Non-peptide fibrinogen receptor antagonists. 2. Optimization of a tyrosine template as a mimic for Arg-Gly-Asp","volume":"37","author":"Egbertson","year":"1994","journal-title":"J Med Chem"},{"issue":"24","key":"10.1378\/chest.11-2293_bib227","doi-asserted-by":"crossref","first-page":"4640","DOI":"10.1021\/jm00102a020","article-title":"Non-peptide fibrinogen receptor antagonists. 1. Discovery and design of exosite inhibitors","volume":"35","author":"Hartman","year":"1992","journal-title":"J Med Chem"},{"issue":"11","key":"10.1378\/chest.11-2293_bib228","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1016\/S0090-9556(24)14939-2","article-title":"In vitro and in vivo studies on the metabolism of tirofiban","volume":"27","author":"Vickers","year":"1999","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"10.1378\/chest.11-2293_bib229","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/0735-1097(95)00500-5","article-title":"Randomized, double-blind, placebo-controlled dose-ranging study of tirofiban (MK-383) platelet IIb\/IIIa blockade in high risk patients undergoing coronary angioplasty","volume":"27","author":"Kereiakes","year":"1996","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1378\/chest.11-2293_bib230","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1023\/A:1008904310194","article-title":"Pharmacokinetics and pharmacodynamics of low-molecular-weight heparins and glycoprotein IIb\/IIIa receptor antagonists in renal failure","volume":"11","author":"Smith","year":"2001","journal-title":"J Thromb Thrombolysis"},{"issue":"20","key":"10.1378\/chest.11-2293_bib231","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1161\/01.CIR.0000016359.94919.16","volume":"105","author":"Januzzi","year":"2002","journal-title":"Circulation"},{"issue":"2","key":"10.1378\/chest.11-2293_bib232","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1182\/blood.V94.2.587","article-title":"Fibrinogen receptor antagonist-induced thrombocytopenia in chimpanzee and rhesus monkey associated with preexisting drug-dependent antibodies to platelet glycoprotein IIb\/IIIa","volume":"94","author":"Bednar","year":"1999","journal-title":"Blood"},{"issue":"6","key":"10.1378\/chest.11-2293_bib233","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1182\/blood.V100.6.2071","article-title":"Acute thrombocytopenia after treatment with tirofiban or eptifibatide is associated with antibodies specific for ligand-occupied GPIIb\/IIIa","volume":"100","author":"Bougie","year":"2002","journal-title":"Blood"},{"issue":"5","key":"10.1378\/chest.11-2293_bib234","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1161\/hc3101.092199","article-title":"Eptifibatide and 7E3, but not tirofiban, inhibit alpha(v)beta(3) integrin-mediated binding of smooth muscle cells to thrombospondin and prothrombin","volume":"104","author":"Lele","year":"2001","journal-title":"Circulation"},{"issue":"2","key":"10.1378\/chest.11-2293_bib235","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/S0021-9258(18)54042-4","article-title":"Design of potent and specific integrin antagonists. Peptide antagonists with high specificity for glycoprotein IIb-IIIa","volume":"268","author":"Scarborough","year":"1993","journal-title":"J Biol Chem"},{"issue":"5","key":"10.1378\/chest.11-2293_bib236","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1161\/01.CIR.96.5.1488","article-title":"Effect of Ca2+ on GP IIb-IIIa interactions with integrilin: enhanced GP IIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate","volume":"96","author":"Phillips","year":"1997","journal-title":"Circulation"},{"issue":"1","key":"10.1378\/chest.11-2293_bib237","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0002-9149(02)02991-0","article-title":"Treatment effects of eptifibatide in planned coronary stent implantation in patients with chronic kidney disease (ESPRIT Trial)","volume":"91","author":"Reddan","year":"2003","journal-title":"Am J Cardiol"},{"issue":"4A","key":"10.1378\/chest.11-2293_bib238","doi-asserted-by":"crossref","first-page":"11B","DOI":"10.1016\/S0002-9149(97)00572-9","article-title":"Clinical pharmacology of eptifibatide","volume":"80","author":"Phillips","year":"1997","journal-title":"Am J Cardiol"},{"issue":"2","key":"10.1378\/chest.11-2293_bib239","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1067\/mhj.2001.116962","article-title":"Comparative efficacy of fibrinogen and platelet supplementation on the in vitro reversibility of competitive glycoprotein IIb\/IIIa (alphaIIb\/beta3) receptor-directed platelet inhibition","volume":"142","author":"Li","year":"2001","journal-title":"Am Heart J"},{"issue":"7","key":"10.1378\/chest.11-2293_bib240","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1056\/NEJM199808133390704","article-title":"The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb\/IIIa with eptifibatide in patients with acute coronary syndromes","volume":"339","year":"1998","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1378\/chest.11-2293_bib241","first-page":"76","article-title":"Eptifibatide-induced acute profound thrombocytopenia presenting as refractory hypotension","volume":"58","author":"Rezkalla","year":"2003","journal-title":"Catheter Cardiovasc Interv"},{"issue":"9063","key":"10.1378\/chest.11-2293_bib242","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/S0140-6736(96)10172-0","article-title":"Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II","volume":"349","author":"The IMPACT-II Investigators","year":"1997","journal-title":"Lancet"},{"issue":"19","key":"10.1378\/chest.11-2293_bib243","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1001\/jama.285.19.2468","article-title":"Platelet glycoprotein IIb\/IIIa integrin blockade with eptifibatide in coronary stent intervention: the ESPRIT trial: a randomized controlled trial","volume":"285","author":"O'Shea","year":"2001","journal-title":"JAMA"},{"issue":"9247","key":"10.1378\/chest.11-2293_bib244","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1016\/S0140-6736(00)03400-0","article-title":"Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial","volume":"356","author":"ESPRIT Investigators","year":"2000","journal-title":"Lancet"},{"issue":"5","key":"10.1378\/chest.11-2293_bib245","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1161\/01.CIR.96.5.1445","volume":"96","year":"1997","journal-title":"Circulation"},{"issue":"9063","key":"10.1378\/chest.11-2293_bib246","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1016\/S0140-6736(96)10452-9","article-title":"Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study","volume":"349","author":"The CAPTURE Investigators","year":"1997","journal-title":"Lancet"},{"issue":"9122","key":"10.1378\/chest.11-2293_bib247","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0140-6736(98)06113-3","article-title":"Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb\/IIIa blockade","volume":"352","author":"EPISTENT Investigators","year":"1998","journal-title":"Lancet"},{"issue":"1","key":"10.1378\/chest.11-2293_bib248","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0002-9343(02)01145-2","article-title":"Multi-year follow-up of abciximab therapy in three randomized, placebo-controlled trials of percutaneous coronary revascularization","volume":"113","author":"Topol","year":"2002","journal-title":"Am J Med"},{"issue":"13","key":"10.1378\/chest.11-2293_bib249","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1056\/NEJMoa013404","article-title":"Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction","volume":"346","author":"Stone","year":"2002","journal-title":"N Engl J Med"},{"issue":"9330","key":"10.1378\/chest.11-2293_bib250","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0140-6736(02)09605-8","article-title":"Outcomes at 6 months for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularisation with stent placement: the TARGET follow-up study","volume":"360","author":"Moliterno","year":"2002","journal-title":"Lancet"},{"issue":"25","key":"10.1378\/chest.11-2293_bib251","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1056\/NEJM200106213442502","article-title":"Do Tirofiban and ReoPro Give Similar Efficacy Trial. Comparison of two platelet glycoprotein IIb\/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization","volume":"344","author":"Topol","year":"2001","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1378\/chest.11-2293_bib252","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/j.1365-2796.2004.01398.x","article-title":"A randomized trial comparing phosphorylcholine-coated stenting with balloon angioplasty as well as abciximab with placebo for restenosis reduction in small coronary arteries","volume":"256","author":"Hausleiter","year":"2004","journal-title":"J Intern Med"},{"issue":"13","key":"10.1378\/chest.11-2293_bib253","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1001\/jama.295.13.joc60034","article-title":"Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial","volume":"295","author":"Kastrati","year":"2006","journal-title":"JAMA"},{"issue":"3","key":"10.1378\/chest.11-2293_bib254","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa031859","article-title":"A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel","volume":"350","author":"Kastrati","year":"2004","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1378\/chest.11-2293_bib255","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1161\/01.CIR.0000148956.93631.4D","article-title":"Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel","volume":"110","author":"Mehilli","year":"2004","journal-title":"Circulation"},{"issue":"9272","key":"10.1378\/chest.11-2293_bib256","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(00)05060-1","article-title":"Effect of glycoprotein IIb\/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial","volume":"357","author":"Simoons","year":"2001","journal-title":"Lancet"},{"issue":"21","key":"10.1378\/chest.11-2293_bib257","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1056\/NEJM199805213382103","article-title":"A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina","volume":"338","author":"Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators","year":"1998","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1378\/chest.11-2293_bib258","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1056\/NEJM199805213382102","article-title":"Inhibition of the platelet glycoprotein IIb\/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction","volume":"338","author":"Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.11-2293_bib259","first-page":"I","article-title":"Randomized trial of potent platelet IIb\/IIIa antagonism, heparin, or both in patients with unstable angina: the PARAGON study [abstract]","volume":"94","author":"Investigators","year":"1996","journal-title":"Circulation"},{"issue":"9329","key":"10.1378\/chest.11-2293_bib260","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/S0140-6736(02)09532-6","article-title":"Platelet glycoprotein IIb\/IIIa inhibitors in acute coronary syndromes","volume":"360","author":"Boersma","year":"2002","journal-title":"Lancet"},{"issue":"17","key":"10.1378\/chest.11-2293_bib261","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1001\/jama.288.17.2130","article-title":"Mortality at 1 year with combination platelet glycoprotein IIb\/IIIa inhibition and reduced-dose fibrinolytic therapy vs conventional fibrinolytic therapy for acute myocardial infarction: GUSTO V randomized trial","volume":"288","author":"Lincoff","year":"2002","journal-title":"JAMA"},{"issue":"21","key":"10.1378\/chest.11-2293_bib262","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1056\/NEJMoa0708191","article-title":"Bivalirudin during primary PCI in acute myocardial infarction","volume":"358","author":"Stone","year":"2008","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1378\/chest.11-2293_bib263","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1161\/CIRCULATIONAHA.108.818617","article-title":"Abciximab in patients with acute ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention after clopidogrel loading: a randomized double-blind trial","volume":"119","author":"Mehilli","year":"2009","journal-title":"Circulation"},{"issue":"22","key":"10.1378\/chest.11-2293_bib264","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1093\/eurheartj\/ehp118","article-title":"Risk profile and benefits from Gp IIb-IIIa inhibitors among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: a meta-regression analysis of randomized trials","volume":"30","author":"De Luca","year":"2009","journal-title":"Eur Heart J"},{"issue":"4","key":"10.1378\/chest.11-2293_bib265","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1161\/01.STR.0000157668.39374.56","article-title":"Emergency administration of abciximab for treatment of patients with acute ischemic stroke: results of a randomized phase 2 trial","volume":"36","author":"Abciximab Emergent Stroke Treatment Trial (AbESTT) Investigators","year":"2005","journal-title":"Stroke"},{"issue":"1","key":"10.1378\/chest.11-2293_bib266","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1161\/STROKEAHA.106.476648","article-title":"Emergency administration of abciximab for treatment of patients with acute ischemic stroke: results of an international phase III trial: Abciximab in Emergency Treatment of Stroke Trial (AbESTT-II)","volume":"39","author":"Adams","year":"2008","journal-title":"Stroke"},{"issue":"12","key":"10.1378\/chest.11-2293_bib267","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1161\/STROKEAHA.108.517656","article-title":"The combined approach to lysis utilizing eptifibatide and rt-PA in acute ischemic stroke: the CLEAR stroke trial","volume":"39","author":"Pancioli","year":"2008","journal-title":"Stroke"}],"container-title":["Chest"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369212601202?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369212601202?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T06:37:32Z","timestamp":1757918252000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0012369212601202"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2]]},"references-count":267,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["S0012369212601202"],"URL":"https:\/\/doi.org\/10.1378\/chest.11-2293","relation":{},"ISSN":["0012-3692"],"issn-type":[{"value":"0012-3692","type":"print"}],"subject":[],"published":{"date-parts":[[2012,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antiplatelet Drugs","name":"articletitle","label":"Article Title"},{"value":"Chest","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1378\/chest.11-2293","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 The American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}